Inoue, Kenichi
Masuda, Norikazu
Iwata, Hiroji
Takahashi, Masato
Ito, Yoshinori
Miyoshi, Yasuo
Nakayama, Takahiro
Mukai, Hirofumi
van der Walt, Jan-Stefan
Mori, Joji
Sakaguchi, Sachi
Kawaguchi, Tsutomu
Tanizawa, Yoshinori
Llombart-Cussac, Antonio
Sledge, George W. Jr
Toi, Masakazu http://orcid.org/0000-0003-1488-9958
Funding for this research was provided by:
Eli Lilly Japan
Article History
Received: 21 December 2020
Accepted: 11 March 2021
First Online: 1 April 2021
Declarationss
:
: Kenichi Inoue reports personal fees and grants to institution from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., and Pfizer Japan; and grants to institution from AstraZeneca, Bayer, MSD, Novartis Pharma K.K., Parexel/Puma Biotechnology, and Taiho Pharmaceutical Co., Ltd. Norikazu Masuda reports personal fees, grants, and other support (research funding to institution) from Chugai Pharmaceutical Co., Ltd. and Eisai Co., Ltd.; personal fees and other support (research funding to institution) from AstraZeneca, Eli Lilly Japan K.K., Pfizer Japan, Inc., Daiichi Sankyo Co., Kyowa Kirin Co. Ltd., Novartis Pharma K.K., and Takeda Pharmaceutical Company, Ltd; and other support (research funding to institution) from MSD and Nippon-Kayaku. Hiroji Iwata reports personal fees and grants from AstraZeneca, Chugai Pharmaceutical Co., Ltd, Daiichi Sankyo Co. Ltd., Eli Lilly Japan K.K., Kyowa Kirin Co. Ltd., Novartis Pharma K.K., and Pfizer Japan, Inc.; grants from Bayer, Boehringer Ingelheim, MSD, Nippon Kayaku, and Sanofi, and personal fees from Eisai Co., Ltd. Masato Takahashi reports personal fees from Astra Zeneca, Eisai Co., Ltd., Eli Lilly Japan K.K., and Pfizer Japan, Inc. Yoshinori Ito reports grants from A2 Healthcare, AstraZeneca, Covance, Chugai Pharmaceutical Co., Ltd, Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., EPS International Holdings Co., Ltd., Kyowa Kirin Co., Ltd., MSD, Novartis Pharma K.K., Parexel, QVIA Services Japan K.K., and Taiho Pharmaceutical Co., Ltd. Yasuo Miyoshi reports personal fees and grants from AstraZeneca, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Kyowa Kirin Co., Ltd., MSD, Pfizer Japan, Inc., and Taiho Pharmaceutical Co., Ltd. Takahiro Nakayama reports personal fees from AstraZeneca, Chugai Pharmaceutical Co., Ltd, Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Novartis Pharma K.K., and Taiho Pharmaceutical Co., Ltd. Hirofumi Mukai reports personal fees and grants from Daiichi Sankyo Co., Ltd. and Pfizer Japan, Inc.; research grants from the Japanese government; personal fees from Taiho Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Company Ltd.; and membership on the Board of Directors of the Japan Breast Cancer Society. Antonio Llombart-Cussac reports grants, personal fees, and non-financial support from AstraZeneca, Eli Lilly and Company, Novartis, Pfizer, and Roche; grants and non-financial support from Eisai Co., Ltd.; grants and personal fees from Genomic Health, Inc. and GSK Tesaro; personal fees and non-financial support from Bristol; personal fees from MSD; and stock, patents, and intellectual property with MedSIR. George W. Sledge, Jr. reports personal fees from Syndax and Verseau, Inc.; grants from Pfizer; and other (board of directors) from Tessa Therapeutics. Masakazu Toi reports personal fees, grants, and other role or support from Daiichi Sankyo Co. Ltd. and Kyowa Kirin Co. Ltd.; personal fees and grants from AstraZeneca, C&C Research Laboratories, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Nippon Kayaku, Pfizer Japan, Inc., Shimadzu, Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company, Ltd., and Yakult; grants and other role or support from Luxonus, Inc.; personal fees and other role or support from Eli Lilly Japan K.K. and Konica Minolta, Inc.; grants from AFI Technologies, Astellas Pharma, Inc., GL Sciences, the Japanese Breast Cancer Research Group Association, and Shionogi; personal fees from Exact Science, Genomic Health, Inc., MSD, and Novartis Pharma K.K.; other role or support from Athenex Oncology, Bertis, Inc., BMS, Terumo Corporation, and Kansai Medical Net; and membership on the Board of Directors of the Japanese Breast Cancer Research Group Association, Organisation for Oncology and Translational Research, and Kyoto Breast Cancer Research Network. Joji Mori, Sachi Sakaguchi, Tsutomu Kawaguchi, and Yoshinori Tanizawa are employees and minor shareholders of Eli Lilly Japan K.K. Jan-Stefan van der Walt is an employee and minor shareholder of Eli Lilly and Company, UK.
: All the procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.